Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke
Nogueira R, Yoo A, Masrur S, Batista L, Hakimelahi R, Hirsch J, Schwamm L. Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke. Journal Of NeuroInterventional Surgery 2012, 5: 298. PMID: 22705875, DOI: 10.1136/neurintsurg-2012-010376.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBrain IschemiaCombined Modality TherapyEndovascular ProceduresFemaleHumansInjections, IntravenousMaleMiddle AgedProspective StudiesRecombinant ProteinsRetrospective StudiesStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeYoung AdultConceptsMultimodal endovascular therapySymptomatic intracranial hemorrhageIntravenous recombinant tissue plasminogen activatorRecombinant tissue plasminogen activatorEndovascular therapyTissue plasminogen activatorParenchymal hematomaSafety endpointHospital dischargeFunctional outcomeFull-dose intravenous recombinant tissue plasminogen activatorPlasminogen activatorIndependent functional outcomeIntravenous rt-PAPrimary safety endpointRt-PA dosageSecondary safety endpointSevere systemic bleedingSimilar safety profileAcute ischemic strokeRate of recanalizationClinical efficacy endpointsT-PA doseBridging therapyGroin hematoma